The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Feasibility and safety of neoadjuvant nivolumab + chemo for resectable diffuse pleural mesotheliomas
Melina Elpi Marmarelis, MD, University of Pennsylvania, Philadelphia, PA, shares results from a pilot study on neoadjuvant nivolumab combined with platinum and pemetrexed for resectable diffuse pleural mesothelioma. Among 22 patients treated, 19 underwent pleurectomy/decortication (P/D), and the study showed promising survival outcomes and tolerability of the regimen. Exploratory analyses identified increased CD8 cytotoxic T cells and ISG+ T cells in patients with better progression-free survival (PFS), highlighting the importance of preoperative treatments. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock and Other Ownership Interests – Bluebird Bio; Gilead Sciences; Johnson & Johnson; Merck; Pfizer; Portola Pharmaceuticals
Honoraria – AstraZeneca; Blueprint Medicines; Blueprint Medicines; Health Advances (I); Janssen Oncology; Novocure; Takeda; Targeted Oncology; Thermo Fisher Scientific
Consulting or Advisory Role – AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Ikena Oncology
Research Funding – AstraZeneca (Inst); Lilly (Inst); Trizell (Inst)
Travel, Accommodations, Expenses – Boehringer Ingelheim; Novocure
